Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/1999
11/02/1999US5977135 Bicyclic heterocycles
11/02/1999US5977130 Intimal hypertrophy inhibitors
11/02/1999US5977121 Use of moxonidine for the treatment of atherosclerosis
11/02/1999US5977118 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones and compositions and methods of use thereof
11/02/1999US5977107 Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists
11/02/1999US5977106 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives
11/02/1999US5977103 Substituted imidazole compounds
11/02/1999US5977095 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
11/02/1999US5977075 N-aroylamino acid amides as endothelin inhibitors
11/02/1999US5976834 cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor
11/02/1999US5976814 DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
11/02/1999US5976534 Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
10/1999
10/28/1999WO1999054469A1 B-cell growth factor related protein
10/28/1999WO1999054351A1 Edg family gene, human h218
10/28/1999WO1999054350A1 Novel omega conotoxin peptides
10/28/1999WO1999054341A1 Enhanced antisense modulation of icam-1
10/28/1999WO1999054333A1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
10/28/1999WO1999054331A1 Novel asymmetrically substituted xanthine derivatives, method for producing them and their use as medicaments with an adenosine-antagonistic effect
10/28/1999WO1999054320A1 Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
10/28/1999WO1999054315A2 Triazolones with a neuroprotective action
10/28/1999WO1999054314A1 Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments
10/28/1999WO1999054311A1 Novel diphenyl-substituted 6-ring-heterocycles, methods for producing them and their use as medicaments
10/28/1999WO1999054310A2 New substituted amides, their production and their use
10/28/1999WO1999054304A1 Heterocyclically substituted amides, their production and their use
10/28/1999WO1999054294A1 New substituted amides, their production and their use
10/28/1999WO1999054293A1 Substituted benzamides, their production and their use as cysteine protease inhibitors
10/28/1999WO1999054284A1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
10/28/1999WO1999054280A1 Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
10/28/1999WO1999053951A1 Terminally-branched polymeric linkers and polymeric conjugates containing the same
10/28/1999WO1999053943A2 Therapeutic angiogenic factors and methods for their use
10/28/1999WO1999053942A1 Compositions comprising osteoprotegerin for the prevention and treatment of cardiovascular diseases
10/28/1999WO1999053928A1 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
10/28/1999WO1999053917A1 Cannabinoids as antioxidants and neuroprotectants
10/28/1999WO1999053910A2 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
10/28/1999WO1999042089A9 Use of thiadiazolo[4,3-a]pyridine derivatives
10/28/1999WO1999024460B1 Dipeptide nitriles
10/28/1999CA2329626A1 Cannabinoids as antioxidants and neuroprotectants
10/28/1999CA2329010A1 Therapeutic angiogenic factors and methods for their use
10/28/1999CA2328720A1 Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
10/28/1999CA2328435A1 New substituted amides, their production and their use
10/28/1999CA2328430A1 Substituted benzamides, their production and their use as cysteine protease inhibitors
10/28/1999CA2328413A1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
10/28/1999CA2328264A1 Novel asymmetrically substituted xanthine derivatives, method for producing them and their use as medicaments with an adenosine-antagonistic effect
10/28/1999CA2325848A1 B-cell growth factor related protein
10/28/1999CA2322759A1 Novel diphenyl-substituted 6-ring-heterocycles, methods for producing them and their use as medicaments
10/27/1999EP0952154A2 N-acyl and N-aroyl aralkyl amides
10/27/1999EP0951906A1 Use of 3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridines for treating heart failure
10/27/1999EP0951471A1 Cycloalkyl inhibitors of protein farnesyltransferase
10/27/1999EP0951467A1 SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE
10/27/1999EP0951293A1 Method for treating alzheimer's disease
10/27/1999EP0951292A1 Methods for treating an ischemic disorder and improving stroke outcome
10/27/1999EP0951285A1 Inhibitors of farnesyl-protein transferase
10/27/1999EP0167575B2 Cardiodilatine, a peptide hormone and production process thereof
10/27/1999CN1233246A Aminothiophene carboxylic acid amides and the use thereof as phosphodiesterase inhibitors
10/27/1999CN1233245A Oxadiazoles, processes for their preparation and their use as medicaments
10/27/1999CN1233238A Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists
10/27/1999CN1233237A Heteroaryl succinamides and their use as metalloproteinase inhibitors
10/27/1999CN1233173A Therapeutic methods and compositions involving isoflavones
10/27/1999CN1233171A Inhibition of nuclear transcription factor NF-'kappa' B by caffeic acid phenethyl ester (CAPE), derivatives of CAPE, capsaicin (8-methyl-N-vanillyl-6-nonenamide) and resiniferatoxin
10/27/1999CN1233169A Process for the manufacture of a pulverous preparation
10/27/1999CN1233150A Method for inhibiting the expression of FAS
10/27/1999CN1232693A Health beverage for preventing and curing hypertension and hyperlipemia
10/26/1999US5973134 Rat CNP complementary DNA and precursor protein
10/26/1999US5973009 Antioxidant and cytoprotecting activity
10/26/1999US5972990 Administering angiotensin ii inhibitors, such as losartan to patients who are otherwise free of indications for angiotensin ii inhibition treatment and have left ventricular ejection fraction of 40% or less
10/26/1999US5972972 Pyrazoles as human non-pancreatic secretory phospholipase A2 inhibitors
10/26/1999US5972970 Oxazolidinedione derivatives, their production and use
10/26/1999US5972965 4,5-diaryl oxazole derivatives
10/26/1999US5972964 Aminomethylindans, -benzofurans and -benzothiophenes
10/26/1999US5972961 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
10/26/1999US5972940 Arginine analogues having nitric oxide synthase inhibitor activity
10/26/1999US5972935 Psychological disordrs, nervous system disorders, parkinson's disorder
10/26/1999US5972928 Administering an antigrowth agent
10/26/1999US5972924 Administering cyclosporin a to a human whose blood-brain barrier has been opened, or where cyclosporin a is able to cross the blood brain barrier
10/26/1999US5972923 Methods and compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants
10/26/1999US5972900 Conjugating target binding moiety consisting of an antibody or fragment which binds to secretory component of polymeric immunoglobulin receptor on surface of epithelium cell, nucleic acid binder, expression vector, compacting, administering
10/26/1999US5972899 Apoptosis induced by Shigella IpaB
10/26/1999US5972894 Peptides having potassium channel opener activity
10/26/1999US5972688 HTm4 methods of treatment and assays, agonists and antagonists
10/26/1999US5972651 Polynucleotides and polypeptides of the fifty-four homologue family, (ffh); vectors and transformed host cells; ffh are components of protein secretory apparatus and their inhibition of function is deleterious to bacteria cells
10/26/1999US5972606 A polypeptide; treating osteoporosis, eating disorders, brain disorders, adult respiratory disease syndrome, huntington'sdisease, ulcers, cardiovascular disorders, parkinson's disease;
10/26/1999CA2183320C Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
10/26/1999CA2177576C Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
10/26/1999CA2163118C Aurintricaboxylic acid fractions and analogues with anti-angiogenic activity and methods of use
10/26/1999CA1340804C Mixed compositions for treating hypercholesterolemia
10/26/1999CA1340798C Disubstituted pyridines
10/21/1999WO1999053052A2 Srebp-2-deficient cell lines
10/21/1999WO1999053036A2 Ste20-related protein kinases
10/21/1999WO1999052946A1 Method for sterilising native collagen in liquid medium, resulting native collagen, compositions containing same and uses
10/21/1999WO1999052932A1 Fatty acid derivatives of bile acids and bile acid derivatives
10/21/1999WO1999052927A1 Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
10/21/1999WO1999052910A1 Bicyclic hydroxamic acid derivatives
10/21/1999WO1999052907A1 Azabicyclic 5ht1 receptor ligands
10/21/1999WO1999052903A1 Prodrugs of benzofuranylmethyl carbamate nk1 antagonists
10/21/1999WO1999052898A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors
10/21/1999WO1999052896A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
10/21/1999WO1999052889A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
10/21/1999WO1999052868A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999WO1999052862A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
10/21/1999WO1999052551A1 Therapy of atherosclerosis
1 ... 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 ... 1595